StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.20 | $1.20 | +0.00% | 0.5M |
| 05-12 | $1.20 | $1.19 | -0.83% | 0.3M |
| 05-13 | $1.20 | $1.19 | -0.83% | 0.3M |
| 05-14 | $1.18 | $1.21 | +2.54% | 0.3M |
| 05-15 | $1.17 | $1.14 | -2.56% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for BTAI.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for BTAI.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $206.00K | $642.00K | $386.00K | $288.00K |
Operating Income | $-10.22M | $-50.46M | $-40.18M | $-25.95M |
Net Income | $-12.69M | $-69.90M | $-57.35M | $-19.19M |
EPS (Diluted) | $-0.54 | $-5.73 | $-6.38 | $-4.17 |
Total Assets | $34.02M | $44.92M | $44.79M | $25.79M |
Total Liabilities | $139.57M | $140.38M | $133.71M | $133.46M |
Cash & Equivalents | $17.18M | $28.41M | $36.18M | $17.43M |
Free Cash Flow OCF − CapEx | $-11.81M | $-57.62M | $-43.41M | $-24.62M |
Shares Outstanding | 27.07M | 22.33M | 20.00M | 6.62M |